logo-loader
viewMotif Bio PLC

Motif Bio lender supportive ahead of key meeting with American regulator

Hercules Capital has pushed out the amortisation date on Motif's loan

Motif Bio PLC -
The company is developing a next-generation antibiotic

Motif Bio PLC (LON:MTFB) said it will pay interest only on its loan from Hercules Capital after the latter pushed out the latest amortisation date a month to October 1 to support Motif’s cash management efforts.

The arrangement comes at a crucial juncture for the UK drug developer, which meets the US Food & Drug Administration on September 19 to agree the details of an additional clinical trial on its antibiotic iclaprim.

“We appreciate the continued support and flexibility of Hercules and the confidence that they have in our team to deliver on our strategic goals,” said chief executive Graham Lumsden.

He added that Motif is “actively pursuing options” to broaden its pipeline.

Thirty days after meeting the FDA to discuss the new trial, minutes will be published by the regulator allowing the firm to update the market.

The FDA wants additional data so it can “further evaluate the risk for liver toxicity” before it decides to grant new drug approval.

In June, Motif released new data for its iclaprim antibiotic at a major industry conference in San Francisco, California.

Three posters were presented at the American Society for Microbiology (ASM) Microbe 2019 meeting.

In August, Motif revealed that it was assessing the potential for iclaprim as a treatment for the life-threatening infection Listeria.

Quick facts: Motif Bio PLC

Price: 0.4767 GBX

AIM:MTFB
Market: AIM
Market Cap: £2.31 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Motif Bio completes rolling submission of NDA for new antibiotic Iclaprim

Graham Lumsden, chief executive of Motif Bio Plc (LON:MTFB), tells Proactive's Andrew Scott they've completed a rolling submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for their new antibiotic Iclaprim. Lumsden says upon acceptance of the filing of...

on 18/6/18

RNS

Holding(s) in Company

1 day, 22 hours ago

Directorate Changes

4 days, 3 hours ago

Result of General Meeting

1 week, 1 day ago

Settlement Agreement

1 week, 5 days ago

Holding(s) in Company

3 weeks, 4 days ago

Holding(s) in Company

4 weeks ago

Second Price Monitoring Extn

4 weeks, 1 day ago

Price Monitoring Extension

4 weeks, 1 day ago

2 min read